Literature DB >> 20708440

Variations in health-related quality of life in Japanese men who underwent iodine-125 permanent brachytherapy for localized prostate cancer.

Nobumichi Tanaka1, Kiyohide Fujimoto, Isao Asakawa, Akihide Hirayama, Tatsuo Yoneda, Katsunori Yoshida, Yoshihiko Hirao, Masatoshi Hasegawa, Noboru Konishi.   

Abstract

PURPOSE: The purpose of this study was to prospectively assess the variations in health-related quality of life (HR-QoL) in patients who underwent low-dose rate prostate brachytherapy using iodine-125 seed source during the first year after seed implantation. METHODS AND MATERIALS: Between July 2004 and December 2006, 109 patients underwent low-dose rate brachytherapy. The Medical Outcomes study 36-Item Short Form; the University of California, Los Angeles-Prostate Cancer Index; and the International Index of Erectile Function-5 were evaluated before and at 1, 3, 6, and 12 months after seed implantation.
RESULTS: In Medical Outcomes study 36-Item Short Form analyses and the HR-QoL scores were well preserved during the first year after seed implantation. In the University of California, Los Angeles-Prostate Cancer Index analyses, the urinary function and bother scores showed significant decrease during 6 months after seed implantation. The bowel function and bother scores showed significant decrease at 3 months after seed implantation. The sexual function score showed significant decrease at 3, 6, and 12 months after seed implantation, whereas the sexual bother score showed no change during the first year. The International Index of Erectile Function-5 score dramatically decreased at 1, 3, 6, and 12 months after seed implantation.
CONCLUSIONS: The general HR-QoL in the patients who underwent seed implantation was well preserved during the first year after seed implantation, whereas the urinary, bowel, and sexual function and bother scores showed transient deterioration during the first year after seed implantation. Especially, sexual function showed significant deterioration in Japanese men after seed implantation.
Copyright © 2010 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20708440     DOI: 10.1016/j.brachy.2009.07.013

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  2 in total

1.  Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute.

Authors:  Makito Miyake; Nobumichi Tanaka; Isao Asakawa; Shunta Hori; Yosuke Morizawa; Yoshihiro Tatsumi; Yasushi Nakai; Takeshi Inoue; Satoshi Anai; Kazumasa Torimoto; Katsuya Aoki; Masatoshi Hasegawa; Tomomi Fujii; Noboru Konishi; Kiyohide Fujimoto
Journal:  BMC Urol       Date:  2017-08-14       Impact factor: 2.264

2.  Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer.

Authors:  Yasushi Nakai; Nobumichi Tanaka; Isao Asakawa; Kazumasa Torimoto; Makito Miyake; Satoshi Anai; Tomomi Fujii; Masatoshi Hasegawa; Kiyohide Fujimoto
Journal:  J Contemp Brachytherapy       Date:  2019-10-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.